Limitations of established antithrombotic strategies

Blood Coagulation and Fibrinolysis

Volumn 10, Issue 6 SUPPL. 2, 1999, Pages

  Haas, S ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bleeding complications; Deep vein thrombosis; Heparin; Heparin induced thrombocytopenia; Low molecular weight heparins; Oral anticoagulants; Prophylaxis failure; Thromboprophylaxis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; DANAPAROID; DERMATAN SULFATE; DESULFATOHIRUDIN; DEXTRAN 70; EFEGATRAN; ENOXAPARIN; GLUCOSE POLYMER; HAPTEN; HEPARAN SULFATE; HEPARIN; HEPARINOID; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PENTASACCHARIDE; THROMBIN INHIBITOR; VITAMIN K GROUP; WARFARIN;

ALOPECIA; BLEEDING; COMPRESSION THERAPY; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG EFFICACY; GASTROINTESTINAL TOXICITY; HUMAN; HYPERVOLEMIA; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PRIORITY JOURNAL; PRURITUS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT FAILURE;

ANTICOAGULANTS; HEPARIN; HUMANS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0032834631     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Ann Surg 1988; 208: 227-240.
2. Clagett GP, Anderson FA, Heit J, Lavine MN, Wheeler HB. Prevention of venous thromboembolism. Chest 1995; 108 (suppl): 312S-334S.
3. Verstraete M. Prophylaxis of venous thromboembolism. BMJ 1997; 314: 123-125.
4. Turpie AGG. Low-molecular-weight heparin: from the bench to the orthopedic patient. Orthopedics 1997; Feb suppl: 10-13.
5. Nicolaides AN, Bergqvist D, Hull R, Ackchurin RS, Allegra C, Arcelus J, et al. Consensus statement: prevention of venous thromboembolism. Int Angiol 1997; 16: 3-38.
6. Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, et al. A comparison of subcutaneous low molecular weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993; 329: 1370-1376.
7. Boneu B. New antithrombotic agents for the prevention and treatment of deep vein thrombosis. Haemostasis 1996; 26 (suppl 4): 368-378.
8. Fareed J, Callas DD, Hoppensteadt DA, Walenga WM, Pifarre R. Current developments in anticoagulant and antithrombotic agents. In: Pifarre R (editor). New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley & Belfus, Inc., 1997; 95-126.
9. Pineo GF, Hull RD. Prevention and treatment of venous thromboembolism. Drugs 1996; 52: 71-92.
10. Turpie AG, Gallus A, Beattie WS, Hirsh J. Prevention of deep vein thrombosis in patients with intracranial disease by intermittent pneumatic compression of the calf. Neurology 1977; 27: 435-438.
11. Fordyce MJF, Ling RSM. A venous foot pump reduced thrombosis after total hip replacement. J Bone Joint Surg 1992; 74: 45-49.
12. Wilson NV, Das SK, Kakkar VV, Maurice HD, Smibert JG, Thomas EM, et al. Thromboembolic prophylaxis in total knee replacement: evaluation of the A-V impulse system. J Bone Joint Surg 1992; 74: 50-52.
13. Rosenberg RA. Actions and interactions of antithrombin and heparin. N Engl J Med 1975; 292: 146-151.
14. Leyvraz PF, Richard J, Bachmann F, Van Melle G, Treyvaud J-M, Livio J-J, et al. Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 1983; 309: 954-958.
15. THRIFT Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992; 305: 567-574.
16. Kakkar VV. Prevention and management of venous thrombosis. Br Med Bull 1994; 50: 871-903.
17. Bergenta S-E. Dextran in the prophylaxis of pulmonary embolism. World J Surg 1978; 2: 19-25.
18. Eskander MBF, Limb D, Stone MH, Furlong AJ, Shardlow D, Stead D, et al. Sequential mechanical and pharmacological thromboprophylaxis in the surgery of hip fractures. Int Orthop 1997; 21: 259-261.
19. Salzman EW, Davies GC. Prophylaxis of venous thromboembolism: analysis of cost-effectiveness. Ann Surg 1980; 191: 207-218.
20. Ansell JE, Price JM, Shah S. Heparin-induced thrombocytopenia: what is its real frequency? Chest 1985; 88: 878-882.
21. Green RM. Treatment of heparin-induced thrombocytopenia and thrombosis. Semin Vasc Surg 1996; 9: 292-295.
22. Barbour LA, Kick SD, Steiner JF, LoVerde ME, Heddleston LN, Lear JL, et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 1994; 170: 862-869.
23. Bergqvist D. Prolonged prophylaxis in postoperative medicine. Semin Thromb Hemost 1997; 23: 149-154.
24. Hunt D. Low-molccular-weight heparins in clinical practice. South Med J 1998; 91: 2-10.
25. Anderson DR, O'Brien BJ, Levine MN, Roberts R, Wells PS, Hirsh J. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep-vein thrombosis after total hip arthroplasty. Ann Intern Med 1993; 119: 1105-1112.
26. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71: 7-11.
27. Shorten GD, Comunale ME. Heparin-induced thrombocytopenia. J Cardiothorac Vasc Anesth 1996; 10: 521-530.
28. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-wcight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
29. Boneu B. Low molecular weight heparin therapy: is monitoring needed? Thromb Haemost 1994; 72: 330-334.
30. Bergqvist D, Lindblad B, Matzsch T. Risk of combining low molecular weight heparin for thromboprophylaxis and epidural or spinal anaesthesia. Semin Thromb Haemost 1993;19: 147-151.
31. Vandermeulen EP, Van Aken J, Vermylen J. Anticoagulants and spinal-epidural anaesthesia. Anesth Analg 1994; 79:1165-1177.
32. Levine M, Raskob G, Landefeld S, Hirsh J. Haemorrhagic complications of anticoagulant treatment. Chest 1995; 108: 276S-290S.
33. Nalbandian R, Mader I, Barrett JL, Rearce JF, Rupp EC. Petechiae, ecchymoses and necrosis of skin induced by coumarin congeners. JAMA 1965; 192: 107-112.
34. Eriksson BI, Wille-Jørgensen P, Kalebo P, Mouret P, Rosencher N, Bosch P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997; 337: 1329-1335.
35. Koza MJ, Lewis BE, Walenga JM, Pifarre R, Fareed J. Antithrombin agents in the management of heparin-induced thrombocytopenia. In: Pifarre R (editor). New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley & Belfus, Inc., 1997; 309-324.
36. Haas S, Walenga JM, Jeske WP, Fareed J. Heparin-induced thrombocytopenia: clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitors. Clin Appl Thromb Haemost 1999; 5: 52-59.